Thursday, November 12, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Is 4% Down In The Last 21 Sessions

USD/CNH Is 4% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 4.48% for the last 21 sessions. At 19:10 EST on Wednesday, 15 March, USD/CNH (USDCNH) is $6.89.

Usd/cnh seeks support around 6.8800 as Chinese retail sales justify expectations

The USD/CNH pair is gauging a cushion around 6.8800 as China's National Bureau of Statistics (NBS) has reported flat Retail Sales (Feb) data.

USD/CNH's yearly highs and lows, it's 0.007% up from its 52-week low and 0.035% down from its 52-week high.

Previous days news about USD/CNH (USDCNH)

  • Usd/cnh price analysis: bounces off 50-dma but bears keep control. According to FXStreet on Tuesday, 14 March, "That said, the USD/CNH pair's latest recovery remains elusive unless the quote stays below the support-turned-resistance line from early February, around 6.9350 by the press time.", "It should be observed that the 7.0000 psychological magnet acts as an extra upside filter before giving control to the USD/CNH bulls."

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com